Effector and enhancing lymphoid cells in plasmacytoma-bearing mice. II. Dynamic changes during tumor progression

✍ Scribed by K. C. Wang; I. Berczi; E. G. Hoffmann; A. H. Sehon

• Publisher: John Wiley and Sons
• Year: 1980
• Tongue: French
• Weight: 701 KB
• Volume: 25
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.2910250411

✦ Synopsis

Abstract

The Winn assay was used for the study of effector (tumor‐inhibiting) and enhancing (tumor‐promoting) lymphoid cells in BALB/c mice bearing MOPC‐104E plasmacytomas. Kinetic studies with thymus, lymphnode, spleen and bone‐marrow cells revealed that spleen, lymph node and to a lesser extent bone‐marrow cells from 7‐ and 10‐day tumor‐bearers inhibited MOPC‐104E growth, while at day 13 all three cell populations enhanced tumor growth. However, at day 16 strong tumor inhibition was observed again by spleen cells and to a lesser extent by lymph‐node cells and thymocytes. Peritoneal cells from normal and tumor‐bearing (7 and 10 days) animals enhanced tumor growth significantly. Separation of spleen cells on nylon wool columns showed that at 10 days the effector cells were T lymphocytes, but at a later stage (35 days) a different effector mechanism was present in the spleen. Treatment of MOPC‐104E recipients with carrageenan or silica had little influence on tumor growth, but marked tumor inhibition occurred after lethal irradiation and bone‐marrow reconstitution. This latter observation, together with the finding that bone‐marrow, lymph node and peritoneal cells from normal donors enhanced tumor growth inseveral experiments, suggests that this plasmacytoma, like hormone‐dependent tumors, requires lymphocyte‐derived growth factors.